PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
September 16, 2025

Supplementary Figure S8 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study

View Full Paper
Ask AI
Bookmark
Share

Authors

CSChantal F. StockemAGAlberto Gil-JimenezHAHamza Ali

Discussion

Loading...

Member takes

Overview

Phase IB NABUCCO study reveals T-cell subsets differ in responders and non-responders to ipilimumab, indicating treatment efficacy.

Key Points

  • T-cell densities at baseline effectively distinguish responders from non-responders in urothelial cancer.
  • In ipilimumab-high cohorts, responders showed significantly higher T-cell densities than non-responders.
  • The analysis focused on T-cell subsets in cohorts receiving ipilimumab-high versus ipilimumab-low treatments.
  • Findings support the potential for T-cell subset analysis in predicting treatment responses in urothelial cancer.

Cite This Study

Stockem et al. (2025) studied this question.

synapsesocial.com/papers/68d4538731b076d99fa589e8https://doi.org/10.1158/1078-0432.30125704
View Full Paper
Ask AI
Bookmark
Share